PharmAthene Newswire

PharmAthene Newswire

Comprehensive Real-Time News Feed for PharmAthene.

Results 1 - 20 of 112 in PharmAthene

  1. Rice Energy Inc. (RICE): Analyst Rating Changes and PT LevelsRead the original story

    Tuesday Feb 14 | The Oak Ridge Observer

    ... Percent. Last time the company reported, NRG Energy , Inc. The 1 analysts offering 12-month price forecasts for PharmAthene Inc have a median target of 6.00, with a high estimate of 6.00 and a low estimate of 6.00. However, the stock is trading at ...

    Comment?

  2. Becker Drapkin Management, L.P. Buys IAC/InterActiveCorp, Turning Point Brands, BGC Partners, ...Read the original story

    Tuesday Feb 14 | GuruFocus.com

    ... The holdings were 342,300 shares as of 2016-12-31. Becker Drapkin Management, L.P. added to the holdings in PharmAthene Inc by 36.68%. The purchase prices were between $2.75 and $3.25, with an estimated average price of $2.99. The stock is now ...

    Comment?

  3. PharmAthene, Inc. (PIP) Cut to C at TheStreetRead the original story w/Photo

    Friday Feb 10 | IntersportsWire

    PharmAthene opened at 1.01 on Monday. PharmAthene has a 52-week low of $0.47 and a 52-week high of $3.50.

    Comment?

  4. PharmAthene, Inc. (PIP) Sees Large Increase in Short InterestRead the original story w/Photo

    Thursday Feb 9 | IntersportsWire

    PharmAthene, Inc. was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 817,562 shares, an increase of 23.9% from the January 13th total of 660,069 shares.

    Comment?

  5. PharmAthene, Inc. (PIP) Cut to C at TheStreetRead the original story w/Photo

    Thursday Feb 9 | Daily Political

    Shares of PharmAthene traded down 8.261% during midday trading on Monday, hitting $1.055. The stock had a trading volume of 6,398,625 shares.

    Comment?

  6. Prescott Group Capital Management, L.l.c. ...Read the original story

    Monday Feb 6 | GuruFocus.com

    Tulsa, OK, based Investment company Prescott Group Capital Management, L.l.c. buys Adeptus Health, Inovalon Holdings, Sequential Brands Group, Canadian Solar, Avon Products, First Solar, VOXX International, Arrowhead Pharmaceuticals, Verso, Berry Plastics Group, sells PharmAthene, Air Transport Services Group, Regional Management, Energy Transfer Equity LP, BioScrip during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, Prescott Group Capital Management, L.l.c.. As of 2016-12-31, Prescott Group Capital Management, L.l.c. owns 159 stocks with a total value of $475 million.

    Comment?

  7. PharmAthene, Inc. (PIP) Short Interest UpdateRead the original story w/Photo

    Thursday Feb 2 | Daily Political

    PharmAthene, Inc. was the recipient of a significant decrease in short interest in January. As of January 13th, there was short interest totalling 660,069 shares, a decrease of 7.3% from the December 30th total of 712,309 shares.

    Comment?

  8. PharmAthene merges with another biotech, will move from AnnapolisRead the original story w/Photo

    Jan 21, 2017 | The Maryland Gazette

    One of the most successful companies ever to come out of the Chesapeake Innovation Center is merging and moving its headquarters out of Annapolis. Defense contractor PharmAthene will merge with private infectious disease biotech Altimmune in an all-stock transaction announced last week.

    Comment?

  9. Tfs Capital Llc Buys Cambrex Corp, Chemtura Corp, Essendant Inc, Sells Liberty TripAdvisor ...Read the original story

    Jan 20, 2017 | GuruFocus.com

    ... purchase was 0.34%. The holdings were 119,396 shares as of 2016-12-31. Tfs Capital Llc added to the holdings in PharmAthene Inc by 566.47%. The purchase prices were between $2.75 and $3.25, with an estimated average price of $2.99. The stock is now ...

    Comment?

  10. Two of region's anthrax-fighting companies announce mergerRead the original story

    Jan 20, 2017 | Business Journal

    Gaithersburg-based immunotherapy company Altimmune Inc. is merging with Annapolis biodefense company PharmAthene Inc. to create a new immunotherapy firm focused on infectious diseases such as anthrax.

    Comment?

  11. Mid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike HigherRead the original story

    Jan 19, 2017 | Benzinga

    ... Meanwhile, top losers in the sector included Sangamo Therapeutics Inc (NASDAQ: SGMO ), down 6 percent, and PharmAthene, Inc. (NYSE: PIP ), down 6 percent. Netflix reported Q4 EPS of $0.15 on revenue of $2.48 billion. Analysts expected earnings of ...

    Comment?

  12. BRIEF-Pharmathene to pay Altimmune termination fee of $2 mln upon termination of dealRead the original story w/Photo

    Jan 19, 2017 | Reuters

    Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms.

    Comment?

  13. BRIEF-Strikepoint signs agreement to purchase IDM's Yukon portfolioRead the original story w/Photo

    Jan 19, 2017 | Reuters

    ... expenditures on yukon properties by December 31, 2017 Source text for Eikon: Further company coverage: * Pharmathene -upon termination of deal under limited specified circumstances following receipt of superior offer, co to pay Altimmune termination ...

    Comment?

  14. RPT-Euro slides, stocks climb as Draghi plays down inflation riseRead the original story w/Photo

    Jan 19, 2017 | Reuters

    ... better-than-expected U.S. economic data, which boosted the dollar across the board. (Reporting by Marc Jones) * Pharmathene -upon termination of deal under limited specified circumstances following receipt of superior offer, co to pay Altimmune ...

    Comment?

  15. Euro zone inflation rise not convincing - DraghiRead the original story w/Photo

    Jan 19, 2017 | Reuters

    ... and it hit a 10-day low against sterling. (Writing by Jeremy Gaunt in LONDON; Editing by Louise Ireland) * Pharmathene -upon termination of deal under limited specified circumstances following receipt of superior offer, co to pay Altimmune ...

    Comment?

  16. PharmAthene, Inc. Release: Company And Altimmune Announce Merger To...Read the original story

    Jan 18, 2017 | BioSpace

    /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an ...

    Comment?

  17. BRIEF-China Oceanwide and IDG Capital report agreement to acquire IDGRead the original story w/Photo

    Jan 19, 2017 | Reuters

    * Pharmathene -upon termination of deal under limited specified circumstances following receipt of superior offer, co to pay Altimmune termination fee of $2 million Source text (http://bit.ly/2k4rmUa) Further company coverage: WASHINGTON, Jan 19 U.S. ...

    Comment?

  18. BRIEF-Pharmathene & Altimmune announces mergerRead the original story w/Photo

    Jan 19, 2017 | Reuters

    ... Altimmune holders will own 58.2% of fully-diluted equity of combined company * Proposed deal does not affect Pharmathene's previously announced special one-time cash dividend of $2.91 per share of common stock * Proposed transaction does not affect ...

    Comment?

  19. PharmAthene, Inc. (PIP) Short Interest Down 14.7% in DecemberRead the original story w/Photo

    Jan 19, 2017 | IntersportsWire

    PharmAthene, Inc. was the recipient of a significant decline in short interest in December. As of December 30th, there was short interest totalling 712,309 shares, a decline of 14.7% from the December 15th total of 835,436 shares.

    Comment?

  20. PharmAthene and Altimmune to merge in all-stock dealRead the original story w/Photo

    Jan 19, 2017 | Seeking Alpha

    PharmAthene and privately held Altimmune ink an agreement to merge in an all-stock transaction. Under the terms of the deal, Altimmune will become a wholly owned subsidiary of PharmAthene although Altimmune shareholders will own 58.2% of the shares in the combined company.

    Comment?